Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $3.1 million.

  • Vivos Therapeutics' Cash & Equivalents fell 5087.94% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 5087.94%. This contributed to the annual value of $6.3 million for FY2024, which is 28101.03% up from last year.
  • Vivos Therapeutics' Cash & Equivalents amounted to $3.1 million in Q3 2025, which was down 5087.94% from $4.4 million recorded in Q2 2025.
  • Vivos Therapeutics' Cash & Equivalents' 5-year high stood at $34.2 million during Q2 2021, with a 5-year trough of $1.0 million in Q3 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $6.3 million (2024), whereas its average is $9.9 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8535.58% in 2022, then surged by 53110.0% in 2024.
  • Over the past 5 years, Vivos Therapeutics' Cash & Equivalents (Quarter) stood at $24.0 million in 2021, then crashed by 85.36% to $3.5 million in 2022, then tumbled by 53.31% to $1.6 million in 2023, then surged by 281.01% to $6.3 million in 2024, then crashed by 50.48% to $3.1 million in 2025.
  • Its Cash & Equivalents was $3.1 million in Q3 2025, compared to $4.4 million in Q2 2025 and $2.3 million in Q1 2025.